{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:56:31Z","timestamp":1792806991791,"version":"4.5.0"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.bioorg.2025.108947","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T23:18:32Z","timestamp":1756768712000},"page":"108947","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Exploring DPP-4: Implications in diverse diseases and structural insights for novel inhibitor design"],"prefix":"10.1016","volume":"165","author":[{"given":"Ritam","family":"Dutta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samima","family":"Khatun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payel","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pramit Kumar","family":"Dey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shovanlal","family":"Gayen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sk. Abdul","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2025.108947_bb0005","first-page":"525","article-title":"The burden and risks of emerging complications of diabetes mellitus, nature reviews","volume":"18","author":"Tomic","year":"2022","journal-title":"Endocrinology"},{"key":"10.1016\/j.bioorg.2025.108947_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115734","article-title":"Diabetes mellitus: classification, mediators, and complications; A gate to identify potential targets for the development of new effective treatments","volume":"168","author":"Antar","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2025.108947_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mcna.2014.08.015","article-title":"Update on Diabetes classification","volume":"99","author":"Thomas","year":"2015","journal-title":"Med. Clin. North Am."},{"key":"10.1016\/j.bioorg.2025.108947_bb0020","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10517-021-05191-7","article-title":"Oxidative stress: Pathogenetic role in Diabetes mellitus and its complications and therapeutic approaches to correction","volume":"171","author":"Darenskaya","year":"2021","journal-title":"Bull. Exp. Biol. Med."},{"key":"10.1016\/j.bioorg.2025.108947_bb0025","doi-asserted-by":"crossref","first-page":"61","DOI":"10.7748\/ns.2021.e11709","article-title":"Diabetes mellitus: an overview of the types, symptoms, complications and management","volume":"37","author":"Cloete","year":"2022","journal-title":"Nurs. Stand."},{"key":"10.1016\/j.bioorg.2025.108947_bb0030","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.16","article-title":"Type 1 diabetes mellitus","volume":"3","author":"Katsarou","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.bioorg.2025.108947_bb0035","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2015.19","article-title":"Type 2 diabetes mellitus","volume":"1","author":"DeFronzo","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.bioorg.2025.108947_bb0040","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-024-01951-9","article-title":"Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy","volume":"9","author":"Lu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2025.108947_bb0045","doi-asserted-by":"crossref","first-page":"11593","DOI":"10.1021\/acs.jmedchem.3c00412","article-title":"Development of long-acting dipeptidyl Peptidase-4 inhibitors: structural evolution and long-acting determinants","volume":"66","author":"Li","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108947_bb0050","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1007\/s40200-024-01479-3","article-title":"Incretin-based therapy: a new horizon in diabetes management","volume":"23","author":"Zarei","year":"2024","journal-title":"J. Diabetes Metab. Disord."},{"key":"10.1016\/j.bioorg.2025.108947_bb0055","first-page":"413","article-title":"Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations, nature reviews","volume":"18","author":"Ke","year":"2022","journal-title":"Endocrinology"},{"key":"10.1016\/j.bioorg.2025.108947_bb0060","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2019.00389","article-title":"Clinical use of DPP-4 inhibitors","volume":"10","author":"Gallwitz","year":"2019","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.bioorg.2025.108947_bb0065","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/s41574-020-0399-8","article-title":"Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus","volume":"16","author":"Deacon","year":"2020","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.bioorg.2025.108947_bb0070","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1021\/jm030628v","article-title":"Dipeptidyl peptidase IV inhibitors for the treatment of Diabetes","volume":"47","author":"Weber","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108947_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116354","article-title":"A review upon medicinal perspective and designing rationale of DPP-4 inhibitors","volume":"46","author":"Kumar","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108947_bb0080","series-title":"Anti-Diabetic Therapies and Cancer: From Bench to Bedside","author":"Kounatidis","year":"2024"},{"key":"10.1016\/j.bioorg.2025.108947_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117464","article-title":"DPP-IV as a potential candidate in anti-obesity and obesity-related diseases treatment","volume":"180","author":"Guo","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2025.108947_bb0090","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.atherosclerosis.2012.09.012","article-title":"An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease","volume":"226","author":"Zhong","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.bioorg.2025.108947_bb0095","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nrd1016","article-title":"How DPP-IV takes a bite","volume":"2","author":"Kirkpatrick","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2025.108947_bb0100","doi-asserted-by":"crossref","first-page":"22489","DOI":"10.1038\/s41598-023-49870-z","article-title":"Use of dipeptidyl peptidase-4 inhibitors was associated with a lower risk of Parkinson's disease in diabetic patients","volume":"13","author":"Lin","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2025.108947_bb0105","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.2337\/dc20-S002","article-title":"2. Classification and diagnosis of Diabetes: standards of medical Care in Diabetes\u20142020","volume":"43","author":"American Diabetes","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bioorg.2025.108947_bb0110","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.973366","article-title":"Diagnostic and therapeutic strategies for non-alcoholic fatty liver disease","volume":"13","author":"Fu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.108947_bb0115","doi-asserted-by":"crossref","first-page":"869","DOI":"10.2337\/diacare.25.5.869","article-title":"Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 Diabetes","volume":"25","author":"Ahr\u00e9n","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bioorg.2025.108947_bb0120","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.2337\/diacare.27.12.2874","article-title":"Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 Diabetes","volume":"27","author":"Ahr\u00e9n","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bioorg.2025.108947_bb0125","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.regpep.2004.06.007","article-title":"What do we know about the secretion and degradation of incretin hormones?","volume":"128","author":"Deacon","year":"2005","journal-title":"Regul. Pept."},{"key":"10.1016\/j.bioorg.2025.108947_bb0130","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/1062936X.2024.2366886","article-title":"Fragment-based QSAR study to explore the structural requirements of DPP-4 inhibitors: a stepping stone towards better type 2 diabetes mellitus management","volume":"35","author":"Dey","year":"2024","journal-title":"SAR QSAR Environ. Res."},{"key":"10.1016\/j.bioorg.2025.108947_bb0135","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.3390\/ijms21082987","article-title":"SGLT2 inhibitor Empagliflozin and DPP4 inhibitor Linagliptin reactivate glomerular autophagy in db\/db mice, a model of type 2 Diabetes","volume":"21","author":"Korbut","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.108947_bb0140","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40265-016-0686-9","article-title":"Sitagliptin: a review in type 2 Diabetes","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2025.108947_bb0145","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3810\/pgm.2011.07.2303","article-title":"Linagliptin: a new DPP-4 inhibitor for the treatment of type 2 Diabetes mellitus","volume":"123","author":"Toth","year":"2011","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.bioorg.2025.108947_bb0150","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s40265-017-0697-1","article-title":"Saxagliptin\/Dapagliflozin: a review in type 2 Diabetes mellitus","volume":"77","author":"Garnock-Jones","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2025.108947_bb0155","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1177\/0897190014522063","article-title":"Alogliptin: safety, efficacy, and clinical implications","volume":"28","author":"Marino","year":"2015","journal-title":"J. Pharm. Pract."},{"key":"10.1016\/j.bioorg.2025.108947_bb0160","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2147\/DMSO.S35682","article-title":"Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes","volume":"6","author":"Kishimoto","year":"2013","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"10.1016\/j.bioorg.2025.108947_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119038","article-title":"Chronic treatment with anti-GIPR mAb alone and combined with DPP-4 inhibitor correct obesity, dyslipidemia and nephropathy in rodent animals","volume":"269","author":"Chen","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.bioorg.2025.108947_bb0170","doi-asserted-by":"crossref","first-page":"5457","DOI":"10.2147\/JIR.S380285","article-title":"DPP4 as a potential candidate in cardiovascular disease","volume":"15","author":"Chen","year":"2022","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.bioorg.2025.108947_bb0175","first-page":"585","article-title":"Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of cardiovascular outcome trials, world","volume":"13","author":"Patoulias","year":"2021","journal-title":"J. Cardiol."},{"key":"10.1016\/j.bioorg.2025.108947_bb0180","doi-asserted-by":"crossref","DOI":"10.1172\/JCI142243","article-title":"Pharmacological treatment of hyperglycemia in type 2 diabetes","volume":"131","author":"Taylor","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bioorg.2025.108947_bb0185","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s12325-008-0076-1","article-title":"DPP4 inhibitors: a new approach in diabetes treatment","volume":"25","author":"Doupis","year":"2008","journal-title":"Adv. Ther."},{"key":"10.1016\/j.bioorg.2025.108947_bb0190","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.bcp.2008.07.029","article-title":"DPP4 inhibitors for diabetes\u2014what next?","volume":"76","author":"Lambeir","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.108947_bb0195","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.diabet.2018.01.011","article-title":"Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: a systematic review and meta-analysis","volume":"44","author":"Cho","year":"2018","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.bioorg.2025.108947_bb0200","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1007\/s12272-016-0813-x","article-title":"DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control","volume":"39","author":"Bae","year":"2016","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.bioorg.2025.108947_bb0205","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/s12276-023-00958-6","article-title":"Evogliptin, a DPP-4 inhibitor, prevents diabetic cardiomyopathy by alleviating cardiac lipotoxicity in db\/db mice","volume":"55","author":"Pham","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.bioorg.2025.108947_bb0210","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.13129","article-title":"Incretin hormones: their role in health and disease","volume":"20","author":"Nauck","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.bioorg.2025.108947_bb0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.diabres.2016.04.027","article-title":"Visceral fat obesity increases serum DPP-4 levels in men with type 2 diabetes mellitus","volume":"116","author":"Tanaka","year":"2016","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.bioorg.2025.108947_bb0220","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s40618-020-01392-5","article-title":"Circulating dipeptidyl peptidase-4 is independently associated with the presence and severity of NAFLD\/NASH in individuals with and without obesity and metabolic disease","volume":"44","author":"Barchetta","year":"2021","journal-title":"J. Endocrinol. Investig."},{"key":"10.1016\/j.bioorg.2025.108947_bb0225","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.2147\/DMSO.S369712","article-title":"Potential effect of DPP-4 inhibitors towards hepatic diseases and associated glucose intolerance","volume":"15","author":"Sharma","year":"2022","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"10.1016\/j.bioorg.2025.108947_bb0230","article-title":"Dipeptidyl peptidase IV inhibitors for nonalcoholic fatty liver disease \u2013 systematic review and Metanalysis","volume":"16","author":"Santos","year":"2020","journal-title":"Curr. Diabetes Rev."},{"key":"10.1016\/j.bioorg.2025.108947_bb0235","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.vph.2011.05.001","article-title":"Cardiovascular effects of DPP-4 inhibition: beyond GLP-1","volume":"55","author":"Fadini","year":"2011","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.108947_bb0240","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/1479164111436236","article-title":"Cardiovascular effects of the DPP-4 inhibitors","volume":"9","author":"Jose","year":"2012","journal-title":"Diab. Vasc. Dis. Res."},{"key":"10.1016\/j.bioorg.2025.108947_bb0245","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.tcm.2017.01.009","article-title":"The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors","volume":"27","author":"Secrest","year":"2017","journal-title":"Trends Cardiovasc. Med."},{"key":"10.1016\/j.bioorg.2025.108947_bb0250","doi-asserted-by":"crossref","first-page":"S276","DOI":"10.2337\/dc11-s229","article-title":"DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors","volume":"34","author":"Dicker","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bioorg.2025.108947_bb0255","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.diabres.2019.02.014","article-title":"Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure","volume":"150","author":"Sinha","year":"2019","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.bioorg.2025.108947_bb0260","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2125.2008.03148.x","article-title":"Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects","volume":"66","author":"Mistry","year":"2008","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.108947_bb0265","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/BF00577838","article-title":"A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide","volume":"7","author":"Hopsu-Havu","year":"1966","journal-title":"Histochemie"},{"key":"10.1016\/j.bioorg.2025.108947_bb0270","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3389\/fendo.2019.00376","article-title":"DPP-4 inhibition and the path to clinical proof","volume":"10","author":"Ahr\u00e9n","year":"2019","journal-title":"Front Endocrinol. (Lausanne)"},{"key":"10.1016\/j.bioorg.2025.108947_bb0275","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1517\/14656566.2012.667078","article-title":"Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus","volume":"13","author":"Guarino","year":"2012","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.bioorg.2025.108947_bb0280","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s40265-014-0199-3","article-title":"Vildagliptin: a review of its use in type 2 Diabetes mellitus","volume":"74","author":"Keating","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2025.108947_bb0285","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1080\/14656566.2020.1803280","article-title":"Efficacy and safety of saxagliptin for the treatment of type 2 diabetes mellitus","volume":"21","author":"Orime","year":"2020","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.bioorg.2025.108947_bb0290","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s40264-019-00857-8","article-title":"Benefit-risk assessment of Alogliptin for the treatment of type 2 Diabetes mellitus","volume":"42","author":"Kaku","year":"2019","journal-title":"Drug Saf."},{"key":"10.1016\/j.bioorg.2025.108947_bb0295","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1007\/s40265-015-0457-z","article-title":"Empagliflozin\/Linagliptin: a review in type 2 Diabetes","volume":"75","author":"Kim","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2025.108947_bb0300","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1177\/08971900221102119","article-title":"Efficacy and safety of Sitagliptin in the treatment of COVID-19","volume":"36","author":"Mikhael","year":"2023","journal-title":"J. Pharm. Pract."},{"key":"10.1016\/j.bioorg.2025.108947_bb0305","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10741-017-9617-4","article-title":"DPP4 inhibitors and cardiovascular outcomes: safety on heart failure","volume":"22","author":"Xia","year":"2017","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.bioorg.2025.108947_bb0310","first-page":"471","article-title":"DPP-4 inhibitors, heart failure and type 2 diabetes: all eyes on safety","volume":"5","author":"Paneni","year":"2015","journal-title":"Cardiovascular Diagnosis Therapy"},{"key":"10.1016\/j.bioorg.2025.108947_bb0315","first-page":"68","article-title":"Clinical safety and tolerability of Vildagliptin - insights from randomised trials, observational studies and post-marketing surveillance","volume":"13","author":"Mathieu","year":"2017","journal-title":"Eur. Endocrinol."},{"key":"10.1016\/j.bioorg.2025.108947_bb0320","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s13098-024-01412-x","article-title":"The multiple actions of dipeptidyl peptidase 4 (DPP-4) and its pharmacological inhibition on bone metabolism: a review","volume":"16","author":"Pechmann","year":"2024","journal-title":"Diabetol. Metab. Syndr."},{"key":"10.1016\/j.bioorg.2025.108947_bb0325","doi-asserted-by":"crossref","DOI":"10.1177\/11795514241288645","article-title":"Prevalence and predictors of adverse events associated with dipeptidyl Peptidase-4 (DPP-4) inhibitors in type 2 diabetic patients: a cross-sectional study","volume":"17","author":"Reghunath","year":"2024","journal-title":"Clin. Med. Insights Endocrinol. Diabetes"},{"key":"10.1016\/j.bioorg.2025.108947_bb0330","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/dmrr.2530","article-title":"The new insights from DPP-4 inhibitors: their potential immune modulatory function in autoimmune diabetes","volume":"30","author":"Zhao","year":"2014","journal-title":"Diabetes Metab. Res. Rev."},{"key":"10.1016\/j.bioorg.2025.108947_bb0335","first-page":"19","article-title":"New insights into the pleiotropic actions of Dipeptidyl Peptidase-4 inhibitors beyond glycaemic control","volume":"20","author":"Mangoura","year":"2024","journal-title":"Touch Rev. Endocrinol."},{"key":"10.1016\/j.bioorg.2025.108947_bb0340","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/1753-0407.12063","article-title":"Dipeptidyl peptidase-4 inhibitors: multitarget drugs, not only antidiabetes drugs","volume":"6","author":"Zhao","year":"2014","journal-title":"J. Diabetes"},{"key":"10.1016\/j.bioorg.2025.108947_bb0345","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1080\/1062936X.2024.2415602","article-title":"Exploring molecular fragments for fraction unbound in human plasma of chemicals: a fragment-based cheminformatics approach","volume":"35","author":"Banerjee","year":"2024","journal-title":"SAR QSAR Environ. Res."},{"key":"10.1016\/j.bioorg.2025.108947_bb0350","doi-asserted-by":"crossref","first-page":"D198","DOI":"10.1093\/nar\/gkl999","article-title":"BindingDB: a web-accessible database of experimentally determined protein\u2013ligand binding affinities","volume":"35","author":"Liu","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bioorg.2025.108947_bb0355","author":"psynlig: A Python package for data visualization"},{"key":"10.1016\/j.bioorg.2025.108947_bb0360","first-page":"48","article-title":"Life beyond the Tanimoto coefficient: similarity measures for interaction fingerprints","volume":"10","author":"R\u00e1cz","year":"2018","journal-title":"J. Chemother."},{"key":"10.1016\/j.bioorg.2025.108947_bb0365","author":"RDKit: Getting started in Python"},{"key":"10.1016\/j.bioorg.2025.108947_bb0370","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1021\/ci8001414","article-title":"Assessing how well a modeling protocol captures a structure\u2212activity landscape","volume":"48","author":"Guha","year":"2008","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bioorg.2025.108947_bb0375","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ejmech.2019.07.045","article-title":"Rapid generation of novel benzoic acid\u2013based xanthine derivatives as highly potent, selective and long acting DPP-4 inhibitors: scaffold-hopping and prodrug study","volume":"180","author":"Li","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108947_bb0380","doi-asserted-by":"crossref","first-page":"5534","DOI":"10.1016\/j.bmc.2016.09.007","article-title":"Scaffold-hopping from xanthines to tricyclic guanines: a case study of dipeptidyl peptidase 4 (DPP4) inhibitors","volume":"24","author":"Pissarnitski","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108947_bb0385","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1016\/j.bmcl.2018.10.019","article-title":"Synthesis, nitric oxide release, and dipeptidyl peptidase-4 inhibition of sitagliptin derivatives as new multifunctional antidiabetic agents","volume":"28","author":"Xie","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108947_bb0390","doi-asserted-by":"crossref","first-page":"6450","DOI":"10.1021\/jm701280z","article-title":"8-(3-(R)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 Diabetes","volume":"50","author":"Eckhardt","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108947_bb0395","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1021\/acs.jmedchem.6b01801","volume":"60","author":"Schwehm","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108947_bb0400","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1021\/acsmedchemlett.6b00027","article-title":"Discovery of novel tricyclic heterocycles as potent and selective DPP-4 inhibitors for the treatment of type 2 Diabetes","volume":"7","author":"Wu","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108947_bb0405","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1016\/j.bmcl.2016.04.020","article-title":"The discovery of novel 5,6,5- and 5,5,6-tricyclic pyrrolidines as potent and selective DPP-4 inhibitors","volume":"26","author":"Cox","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108947_bb0410","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ejmech.2017.10.029","article-title":"Rapid generation of a novel DPP-4 inhibitor with long-acting properties: SAR study and PK\/PD evaluation","volume":"141","author":"Xie","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108947_bb0415","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.bmc.2018.01.006","article-title":"Surrogating and redirection of pyrazolo[1,5-a]pyrimidin-7(4H)-one core, a novel class of potent and selective DPP-4 inhibitors","volume":"26","author":"Deng","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108947_bb0420","doi-asserted-by":"crossref","first-page":"4428","DOI":"10.1016\/j.bmcl.2015.09.015","article-title":"Design, synthesis and biological evaluation of novel pyrazolo-pyrimidinones as DPP-IV inhibitors in diabetes","volume":"25","author":"Sagar","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108947_bb0425","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.bioorg.2017.02.004","article-title":"Design and synthesis of quinazoline-3,4-(4H)-diamine endowed with thiazoline moiety as new class for DPP-4 and DPPH inhibitor","volume":"71","author":"Ali","year":"2017","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108947_bb0430","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1021\/ml100200c","article-title":"Design, synthesis, and in vitro evaluation of novel Aminomethyl-pyridines as DPP-4 inhibitors","volume":"1","author":"Kaczanowska","year":"2010","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108947_bb0435","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1021\/jm101236h","article-title":"Discovery of a 3-Pyridylacetic acid derivative (TAK-100) as a potent, selective and orally active dipeptidyl peptidase IV (DPP-4) inhibitor","volume":"54","author":"Miyamoto","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108947_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111912","article-title":"Synthesis and discovery of triazolo-pyridazine-6-yl-substituted piperazines as effective anti-diabetic drugs; evaluated over dipeptidyl peptidase-4 inhibition mechanism and insulinotropic activities","volume":"187","author":"Bindu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108947_bb0445","doi-asserted-by":"crossref","first-page":"5033","DOI":"10.1016\/j.bmc.2012.06.033","article-title":"Fused bicyclic heteroarylpiperazine-substituted l-prolylthiazolidines as highly potent DPP-4 inhibitors lacking the electrophilic nitrile group","volume":"20","author":"Yoshida","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108947_bb0450","doi-asserted-by":"crossref","first-page":"5705","DOI":"10.1016\/j.bmc.2012.08.012","volume":"20","author":"Yoshida","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108947_bb0455","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1021\/jm070330v","article-title":"Discovery of potent and selective dipeptidyl peptidase IV inhibitors derived from \u03b2-Aminoamides bearing Subsituted Triazolopiperazines","volume":"51","author":"Kim","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108947_bb0460","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.bmc.2013.01.062","article-title":"Discovery of potent dipeptidyl peptidase IV inhibitors through pharmacophore hybridization and hit-to-lead optimization","volume":"21","author":"Zeng","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108947_bb0465","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1021\/jm030091l","article-title":"1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with Antihyperglycemic properties","volume":"46","author":"Villhauer","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108947_bb0470","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1021\/jm981033g","article-title":"Structure\u2212activity relationship of Diaryl phosphonate esters as potent irreversible dipeptidyl peptidase IV inhibitors","volume":"42","author":"Belyaev","year":"1999","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108947_bb0475","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.bmc.2019.01.001","article-title":"Identification of novel uracil derivatives incorporating benzoic acid moieties as highly potent dipeptidyl peptidase-IV inhibitors","volume":"27","author":"Huang","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108947_bb0480","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1021\/jm950732f","article-title":"Structure\u2212activity relationships of Boronic acid inhibitors of dipeptidyl peptidase IV. 1. Variation of the P2 position of Xaa-boroPro dipeptides","volume":"39","author":"Coutts","year":"1996","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108947_bb0485","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1016\/j.bmc.2011.06.059","article-title":"Identification of 3-aminomethyl-1,2-dihydro-4-phenyl-1-isoquinolones: a new class of potent, selective, and orally active non-peptide dipeptidyl peptidase IV inhibitors that form a unique interaction with Lys554","volume":"19","author":"Banno","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108947_bb0490","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1021\/jm061321+","article-title":"Synthesis and characterization of constrained Peptidomimetic dipeptidyl peptidase IV inhibitors: amino-lactam boroAlanines","volume":"50","author":"Lai","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108947_bb0495","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1021\/jm0507781","article-title":"2-[3-[2-[(2S)-2-Cyano-1-pyrrolidinyl]-2-oxoethylamino]-3-methyl-1-oxobutyl]- 1,2,3,4-tetrahydroisoquinoline: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV","volume":"49","author":"Tsu","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108947_bb0500","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1021\/acsmedchemlett.5b00074","article-title":"Design, synthesis, and pharmacological evaluation of fused \u03b2-Homophenylalanine derivatives as potent DPP-4 inhibitors","volume":"6","author":"Jiang","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108947_bb0505","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1016\/j.bmcl.2017.05.048","article-title":"Design of potent dipeptidyl peptidase IV (DPP-4) inhibitors by employing a strategy to form a salt bridge with Lys554","volume":"27","author":"Maezaki","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108947_bb0510","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1021\/jm070104l","article-title":"Discovery of Alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV","volume":"50","author":"Feng","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108947_bb0515","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.bmc.2014.12.051","article-title":"Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors: use of a carboxylate prodrug to improve bioavailability","volume":"23","author":"Ikuma","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108947_bb0520","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejmech.2016.08.023","article-title":"Discovery of novel xanthine compounds targeting DPP-IV and GPR119 as anti-diabetic agents","volume":"124","author":"Li","year":"2016","journal-title":"Eur. J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825008272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825008272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T20:24:05Z","timestamp":1760559845000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825008272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":104,"alternative-id":["S0045206825008272"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108947","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring DPP-4: Implications in diverse diseases and structural insights for novel inhibitor design","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108947","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108947"}}